Strategies Wealth Advisors LLC Takes $261,000 Position in Pfizer Inc. $PFE

Key Points

• Strategies Wealth Advisors LLC has acquired 10,290 shares of Pfizer Inc. ($PFE), valued at approximately $261,000, during the first quarter.
• Pfizer reported a $0.78 EPS for its latest quarter, exceeding estimates and showing a 10.3% increase in revenue year-over-year.
• The company announced a quarterly dividend of $0.43 per share, translating to an annualized yield of 6.7%.

Strategies Wealth Advisors LLC bought a new stake in Pfizer Inc. (NYSE:PFE - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 10,290 shares of the biopharmaceutical company's stock, valued at approximately $261,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PFE. Bessemer Group Inc. boosted its stake in shares of Pfizer by 11.1% during the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock worth $3,358,000 after acquiring an additional 13,228 shares in the last quarter. Capital Advisors Inc. OK boosted its stake in shares of Pfizer by 1.2% during the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock worth $35,817,000 after acquiring an additional 17,032 shares in the last quarter. CHURCHILL MANAGEMENT Corp bought a new stake in shares of Pfizer during the 1st quarter worth about $8,283,000. Alta Advisers Ltd boosted its stake in shares of Pfizer by 69.6% during the 1st quarter. Alta Advisers Ltd now owns 31,912 shares of the biopharmaceutical company's stock worth $809,000 after acquiring an additional 13,100 shares in the last quarter. Finally, WCM Investment Management LLC boosted its stake in shares of Pfizer by 8.7% during the 1st quarter. WCM Investment Management LLC now owns 125,964 shares of the biopharmaceutical company's stock worth $3,176,000 after acquiring an additional 10,051 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on PFE. Leerink Partners decreased their price target on Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a research note on Wednesday, April 30th. Bank of America upped their price target on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Citigroup upped their price target on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. HSBC decreased their price target on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research note on Monday, May 19th. Finally, Morgan Stanley boosted their price objective on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Pfizer has a consensus rating of "Hold" and a consensus target price of $28.12.

Pfizer Stock Performance

Pfizer stock traded down $0.73 during trading hours on Monday, hitting $25.15. The stock had a trading volume of 32,304,503 shares, compared to its average volume of 45,249,543. The company has a 50-day moving average of $24.70 and a two-hundred day moving average of $24.39. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The company has a market cap of $142.99 billion, a PE ratio of 13.38, a price-to-earnings-growth ratio of 0.92 and a beta of 0.52. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company's revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 6.8%. Pfizer's dividend payout ratio is 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.